Immunocore
IMCR
133 hedge funds and large institutions have $2.56B invested in Immunocore in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 15 closing their positions.
375% more call options, than puts
Call options by funds: $26.7M | Put options by funds: $5.62M
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
34% more capital invested
Capital invested by funds: $1.92B → $2.56B (+$646M)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
14% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 44
6% more funds holding
Funds holding: 125 → 133 (+8)
1.18% more ownership
Funds ownership: 76.82% → 78.01% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$49.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$20.7M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$19.5M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$13.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$31.9M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$23.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.9M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$15.4M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$14.7M |
IMCR Hedge Fund Activity: Q4 2023 in Review
133 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q4 2023, worth a combined $2.56B — up 34% from $1.92B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new IMCR positions and 15 closed out — a net gain of 8 holders — while 50 added to existing stakes and 44 trimmed.
The largest buyer was Bellevue Group, adding an estimated $49.7M. The largest seller was First Manhattan, exiting entirely with an estimated $31.9M sold.
- 133 institutional investors held Immunocore (IMCR) as of Q4 2023, up from 125 in Q3 2023.
- Funds reported $2.56B of Immunocore stock for Q4 2023, up 34% quarter-over-quarter.
- 23 funds opened new Immunocore positions in Q4 2023 and 15 closed out, a net change of +8 holders.
- The largest Immunocore buyer in Q4 2023 was Bellevue Group, an estimated $49.7M added.
- The largest Immunocore seller in Q4 2023 was First Manhattan, an estimated $31.9M sold.
Based on aggregated 13F filings for Q4 2023.